NASDAQ:ALLK Allakos (ALLK) Stock Price, News & Analysis → Does this make you sick? (From Allegiance Gold) (Ad) Free ALLK Stock Alerts $1.45 +0.02 (+1.40%) (As of 12:15 PM ET) Add Compare Share Share Today's Range$1.41▼$1.4950-Day Range$1.01▼$1.4552-Week Range$0.98▼$5.64Volume75,885 shsAverage Volume1.11 million shsMarket Capitalization$128.38 millionP/E RatioN/ADividend YieldN/APrice Target$1.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Allakos alerts: Email Address Allakos MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside27.3% Upside$1.83 Price TargetShort InterestBearish6.31% of Shares Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.34) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.05 out of 5 starsMedical Sector213th out of 918 stocksPharmaceutical Preparations Industry89th out of 421 stocks 3.1 Analyst's Opinion Consensus RatingAllakos has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageAllakos has received no research coverage in the past 90 days.Read more about Allakos' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.31% of the outstanding shares of Allakos have been sold short.Short Interest Ratio / Days to CoverAllakos has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Allakos has recently decreased by 1.93%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAllakos does not currently pay a dividend.Dividend GrowthAllakos does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAllakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Allakos is -0.86. Previous Next 1.7 News and Social Media Coverage News SentimentAllakos has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Allakos this week, compared to 1 article on an average week.Search Interest3 people have searched for ALLK on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allakos insiders have not sold or bought any company stock.Percentage Held by Insiders16.12% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.64% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Allakos' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Allakos are expected to grow in the coming year, from ($1.34) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allakos is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allakos is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllakos has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Allakos' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About Allakos Stock (NASDAQ:ALLK)Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Read More ALLK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLK Stock News HeadlinesMay 15, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)May 10, 2024 | finanznachrichten.deAllakos Inc.: Allakos Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 10, 2024 | finance.yahoo.comAllakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings PredictionsMay 10, 2024 | markets.businessinsider.comAllakos Buy Rating: Clinical Promise and Financial Stability Drive Positive OutlookMay 9, 2024 | investorplace.comALLK Stock Earnings: Allakos Meets EPS for Q1 2024May 9, 2024 | globenewswire.comAllakos Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 3, 2024 | finance.yahoo.comWith 55% ownership of the shares, Allakos Inc. (NASDAQ:ALLK) is heavily dominated by institutional ownersApril 24, 2024 | markets.businessinsider.comMarket Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical DevelopmentsApril 9, 2024 | investorplace.com3 Biotech Stocks to Dump Before They Go to ZeroMarch 19, 2024 | markets.businessinsider.comHold Rating on Allakos Amidst Cautious Optimism for AK006 ProgramMarch 16, 2024 | finance.yahoo.comAllakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4March 15, 2024 | markets.businessinsider.comHold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 DevelopmentsMarch 15, 2024 | markets.businessinsider.comBuy Rating Maintained for Century Therapeutics with Increased Price Target Amid Promising Trials and Strong FinancialsMarch 15, 2024 | markets.businessinsider.comTD Cowen Remains a Hold on Allakos (ALLK)March 14, 2024 | investorplace.comALLK Stock Earnings: Allakos Misses EPS for Q4 2023March 14, 2024 | globenewswire.comAllakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | finanznachrichten.deAllakos Inc.: Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024February 26, 2024 | globenewswire.comAllakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024February 17, 2024 | finance.yahoo.comALLK Sep 2024 2.000 callFebruary 17, 2024 | finance.yahoo.comALLK Sep 2024 2.500 callFebruary 17, 2024 | finance.yahoo.comALLK Mar 2024 1.500 callFebruary 12, 2024 | finanznachrichten.deAllakos Inc.: Allakos Announces Publication Highlighting AK006 Mast Cell InhibitionFebruary 12, 2024 | finance.yahoo.comAllakos Announces Publication Highlighting AK006 Mast Cell InhibitionJanuary 28, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLKJanuary 18, 2024 | finance.yahoo.comHere's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 WeeksSee More Headlines Receive ALLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/21/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALLK CUSIPN/A CIK1564824 Webwww.allakos.com Phone(650) 597-5002FaxN/AEmployees131Year FoundedN/APrice Target and Rating Average Stock Price Target$1.83 High Stock Price Target$3.00 Low Stock Price Target$1.00 Potential Upside/Downside+28.2%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-185,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-99.88% Return on Assets-73.06% Debt Debt-to-Equity RatioN/A Current Ratio4.11 Quick Ratio4.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.93 per share Price / Book0.74Miscellaneous Outstanding Shares88,540,000Free Float74,271,000Market Cap$126.61 million OptionableOptionable Beta0.86 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Robert Alexander Ph.D. (Age 54)CEO & Director Comp: $1.5MDr. Adam L. Tomasi Ph.D. (Age 54)President Comp: $1.15MMr. Baird Radford III (Age 54)Chief Financial Officer Comp: $731.35kMs. Mary Cromwell Ph.D.Chief Technical OfficerDr. Chin Lee M.D. (Age 54)M.P.H., Chief Medical Officer Mr. Alan ChangDirector of Medical Affairs & Data AnalyticsMore ExecutivesKey CompetitorsConnect BiopharmaNASDAQ:CNTBCyteir TherapeuticsNASDAQ:CYTTAdicet BioNASDAQ:ACETRelmada TherapeuticsNASDAQ:RLMDBeyondSpringNASDAQ:BYSIView All CompetitorsInstitutional OwnershipIkarian Capital LLCBought 695,619 shares on 5/17/2024Ownership: 1.053%BVF Inc. ILBought 8,000,000 shares on 5/16/2024Ownership: 18.695%Redmile Group LLCSold 219,371 shares on 5/16/2024Ownership: 3.898%Price T Rowe Associates Inc. MDSold 7,282,606 shares on 5/15/2024Ownership: 0.721%Platinum Investment Management Ltd.Bought 537,038 shares on 5/14/2024Ownership: 1.324%View All Institutional Transactions ALLK Stock Analysis - Frequently Asked Questions Should I buy or sell Allakos stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares. View ALLK analyst ratings or view top-rated stocks. What is Allakos' stock price target for 2024? 5 analysts have issued twelve-month target prices for Allakos' shares. Their ALLK share price targets range from $1.00 to $3.00. On average, they predict the company's stock price to reach $1.83 in the next twelve months. This suggests a possible upside of 27.3% from the stock's current price. View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts. How have ALLK shares performed in 2024? Allakos' stock was trading at $2.73 at the beginning of 2024. Since then, ALLK shares have decreased by 47.3% and is now trading at $1.44. View the best growth stocks for 2024 here. When is Allakos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our ALLK earnings forecast. How were Allakos' earnings last quarter? Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.09. What other stocks do shareholders of Allakos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS). When did Allakos IPO? Allakos (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager. Who are Allakos' major shareholders? Allakos' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (18.69%), Vanguard Group Inc. (4.29%), Redmile Group LLC (3.90%), Acadian Asset Management LLC (1.50%), Platinum Investment Management Ltd. (1.32%) and Ikarian Capital LLC (1.05%). Insiders that own company stock include Adam Tomasi, Henrik S Md Rasmussen, Paul Edward Walker, Robert Alexander and Steven P James. View institutional ownership trends. How do I buy shares of Allakos? Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALLK) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsNext President (Not Trump. Not Biden.)The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.